All Photos(1)

Documents

Y0001587

Atomoxetine for impurity A identification

Name: Atomoxetine for impurity A identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(R)-Tomoxetine hydrochloride, (R)-N-Methyl-γ-(2-methylphenoxy)benzenepropanamine hydrochloride, Atomoxetine hydrochloride

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₇H₂₁NO · HCl

CAS Number:

82248-59-7

Molecular Weight:

291.82

MDL number:

MFCD06410992

UNSPSC Code:

41116107

PubChem Substance ID:

329831497

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

atomoxetine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

InChI key

LUCXVPAZUDVVBT-UNTBIKODSA-N

Gene Information

human ... SLC6A2(6530)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Atomoxetine for impurity A identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Norepinephrine uptake blocker.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1044488

1044491

1044470

PHR1679

Atomoxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2840

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting impulsivity in Parkinson's disease using atomoxetine.

Angie A Kehagia et al.

Brain : a journal of neurology, 137(Pt 7), 1986-1997 (2014-06-05)

Noradrenergic dysfunction may play a significant role in cognition in Parkinson's disease due to the early degeneration of the locus coeruleus. Converging evidence from patient and animal studies points to the role of noradrenaline in dopaminergically insensitive aspects of the

Addressing the unique issues of student athletes with ADHD.

Adam E Perrin et al.

The Journal of family practice, 63(5), E1-E9 (2014-05-06)

Atomoxetine-induced mydriasis in a child patient.

Kayhan Bahali et al.

European child & adolescent psychiatry, 23(12), 1231-1232 (2013-11-12)

Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.

Chloe J Jordan et al.

Drug and alcohol dependence, 140, 25-32 (2014-05-09)

Attention-deficit/hyperactivity disorder (ADHD) is often comorbid with cocaine abuse. Controversy exists regarding long-term consequences of ADHD medications on cocaine abuse liability. Whereas childhood methylphenidate treatment may be preventative, methylphenidate in teens appears to further increase later cocaine abuse risk. In

Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.

Joshua Caballero et al.

Clinical therapeutics, 25(12), 3065-3083 (2004-01-30)

Attention-deficit/hyperactivity disorder (ADHD) occurs in approximately 3% to 10% of the pediatric population. Most of the drugs typically used to treat ADHD are stimulants, which, because of their addictive properties and potential for abuse, are controlled substances. Although these drugs

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service